AI-Enhanced Radiotherapy Planning QA Market 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

AI-Enhanced Radiotherapy Planning QA Market Outlook

According to our latest research, the global AI-Enhanced Radiotherapy Planning QA market size reached USD 497.3 million in 2025, and is expected to grow at a robust CAGR of 18.6% from 2026 to 2034. By the end of 2034, the market is forecasted to achieve a valuation of USD 2,498.7 million. This significant expansion is driven by the increasing adoption of artificial intelligence in oncology, the need for enhanced accuracy and efficiency in radiotherapy planning, and the growing global cancer burden. Technological advancements and the integration of AI-powered quality assurance solutions are revolutionizing the radiotherapy planning landscape in 2025, ensuring safer and more effective cancer treatment modalities worldwide.

Get Free Sample Report

One of the primary growth factors fueling the AI-Enhanced Radiotherapy Planning QA market is the rising global incidence of cancer, which has led to a surge in demand for advanced radiotherapy solutions. With more than 20 million new cancer cases projected annually by 2026, healthcare systems are under immense pressure to deliver high-precision, patient-specific treatments. Artificial intelligence plays a crucial role in automating and optimizing the quality assurance process in radiotherapy planning, thereby reducing human error and improving treatment outcomes. The integration of AI-driven QA tools streamlines workflows, enhances the reproducibility of treatment plans, and ensures adherence to stringent safety standards. This is particularly important in complex oncological cases, where manual QA processes are time-consuming and prone to variability. The broader field of radiotherapy planning AI is expanding rapidly, creating a fertile ecosystem for QA innovation.

Another significant driver for market growth is the rapid advancement of AI algorithms, machine learning, and deep learning techniques. These innovations are enabling more sophisticated analysis of medical images, automated dose calculations, and real-time treatment plan verification. AI-powered solutions can rapidly analyze vast datasets from multiple sources, including CT, MRI, and PET scans, to identify subtle patterns and anomalies that may be overlooked by human reviewers. This not only accelerates the QA process but also enhances the accuracy and consistency of radiotherapy planning. Furthermore, the integration of AI with cloud-based platforms is facilitating remote collaboration among multidisciplinary teams, enabling experts to review and validate treatment plans irrespective of geographical constraints. Such developments are particularly beneficial in resource-limited settings, where access to specialized expertise may be limited. Parallel advances in AI-driven radiology dose optimization are also reinforcing the clinical case for automated QA workflows across radiation oncology departments.

The growing emphasis on patient safety and regulatory compliance is also propelling the adoption of AI-Enhanced Radiotherapy Planning QA solutions. Regulatory bodies such as the FDA and EMA continue to impose stricter guidelines for the validation and verification of radiotherapy treatment plans, necessitating the use of advanced QA tools. AI-driven platforms offer comprehensive audit trails, automated documentation, and real-time reporting capabilities, ensuring that healthcare providers meet regulatory requirements with ease. Additionally, the increasing focus on value-based healthcare and cost containment is prompting hospitals and cancer treatment centers to invest in AI-powered QA solutions that deliver improved efficiency, reduced operational costs, and better patient outcomes. This trend is expected to accelerate through the 2026-2034 forecast period as payers and providers seek to maximize the value of oncological care through automation and intelligent decision support.

Adaptive radiotherapy software is becoming an integral part of the radiotherapy planning landscape, offering dynamic solutions that adjust treatment plans in response to real-time patient data. This software leverages advanced algorithms to continuously monitor and modify radiation doses based on changes in tumor size, shape, and position, thus enhancing treatment precision and effectiveness. By integrating adaptive capabilities, healthcare providers can offer more personalized and responsive cancer care, reducing the risk of overexposure to healthy tissues and improving patient outcomes. The implementation of adaptive planning tools is particularly beneficial in complex cases where tumors exhibit significant variability, as it ensures that treatment remains aligned with the evolving clinical scenario. As the demand for precision oncology grows through 2034, the adoption of adaptive software solutions is expected to rise alongside AI-enhanced QA platforms.

From a regional perspective, North America currently dominates the AI-Enhanced Radiotherapy Planning QA market, accounting for approximately 40.5% of global revenue in 2025. The region's leadership is attributed to advanced healthcare infrastructure, a high concentration of leading technology providers, and significant investments in cancer research. Europe follows closely with a 26.0% share, driven by increasing government initiatives to modernize oncology care and the widespread adoption of AI technologies in healthcare. The Asia Pacific region, holding a 21.5% share in 2025, is expected to witness the highest growth rate over the forecast period, fueled by rising cancer prevalence, improving healthcare infrastructure, and growing awareness of the benefits of AI-enhanced radiotherapy planning. Latin America and the Middle East and Africa, with shares of 7.0% and 5.0% respectively, are also projected to experience steady growth as healthcare systems in these regions continue to evolve and adopt advanced cancer treatment modalities.

Component Analysis

The Component segment of the AI-Enhanced Radiotherapy Planning QA market is divided into software, hardware, and services, each playing a pivotal role in the overall ecosystem. Software is the linchpin of this market, accounting for approximately 58.5% of total revenue in 2025 and encompassing AI-driven algorithms and platforms that automate and validate radiotherapy plans. These software solutions leverage machine learning and deep learning techniques to analyze medical images, optimize dose distributions, and detect potential errors in treatment planning. Leading vendors are continuously enhancing their offerings with advanced features such as adaptive planning, real-time analytics, and predictive modeling, which significantly improve the precision and efficiency of radiotherapy QA processes. The demand for robust, user-friendly, and interoperable radiotherapy plan quality assurance software is expected to remain strong as healthcare providers seek to streamline workflows and ensure regulatory compliance throughout the 2026-2034 period.

Get Free Sample Report

Hardware forms the backbone of AI-Enhanced Radiotherapy Planning QA systems, contributing around 22.0% of market revenue in 2025 and providing the computational power required to run complex AI algorithms and process large volumes of imaging data. This segment includes high-performance servers, GPUs, storage devices, and specialized imaging equipment that facilitate the seamless integration of AI-driven QA tools into existing radiotherapy workflows. Advances in hardware technology, such as the development of more powerful and energy-efficient processors and next-generation GPU architectures, are enabling faster data processing and real-time plan verification. The adoption of cloud-based infrastructure is also gaining traction, allowing healthcare providers to scale their hardware resources on demand and support collaborative care models. As the complexity of radiotherapy planning increases with modalities such as FLASH radiotherapy and MR-guided treatments, the need for robust and scalable hardware solutions will become even more pronounced. Progress in FLASH radiotherapy beam QA systems is one example of how specialized hardware innovation is reshaping quality assurance requirements.

Services are an integral component of the market, accounting for approximately 19.5% of revenue in 2025 and encompassing a wide range of offerings such as implementation, training, consulting, and maintenance. As the adoption of AI-Enhanced Radiotherapy Planning QA solutions accelerates, healthcare providers are increasingly seeking expert guidance to ensure seamless integration with existing systems and workflows. Service providers offer comprehensive support throughout the solution lifecycle, from initial needs assessment and customization to ongoing technical support and updates. Training programs are particularly critical, as they equip clinicians and medical physicists with the necessary skills to effectively utilize AI-driven QA tools. The growing complexity of radiotherapy planning and the rapid pace of technological innovation are expected to drive sustained demand for high-quality services across the forecast period.

The interplay between software, hardware, and services is critical to the successful implementation of AI-Enhanced Radiotherapy Planning QA solutions. Vendors are increasingly adopting a holistic approach, offering integrated solutions that combine advanced software platforms with purpose-built hardware and comprehensive support services. This integrated approach not only simplifies procurement and deployment for healthcare providers but also ensures optimal performance and interoperability. As the market continues to evolve through 2034, we expect to see greater emphasis on end-to-end solutions that address the full spectrum of radiotherapy planning QA needs, from data acquisition and analysis to plan validation and reporting.

In summary, the Component segment is characterized by rapid innovation and increasing convergence between software, hardware, and services. Each sub-segment plays a distinct yet complementary role in enhancing the quality, safety, and efficiency of radiotherapy planning. As AI technologies continue to mature and healthcare providers seek to optimize oncological care, the demand for integrated, scalable, and user-centric QA solutions is expected to drive sustained growth across all components of the market through 2034.

Report Scope

Application Analysis

The Application segment of the AI-Enhanced Radiotherapy Planning QA market encompasses a diverse range of use cases, including treatment planning, dose calculation, image analysis, workflow automation, and others. Treatment planning is the largest and most critical application, as it involves the creation of highly individualized radiation delivery plans tailored to each patient's anatomy and tumor characteristics. AI-driven QA solutions play a pivotal role in automating the validation of these plans, ensuring that they meet clinical objectives and adhere to safety standards. By leveraging advanced algorithms, these solutions can rapidly identify potential errors, inconsistencies, or deviations from protocol, thereby enhancing the accuracy and reliability of treatment planning. The growing complexity of modern radiotherapy techniques, such as IMRT, VMAT, and stereotactic body radiotherapy (SBRT), underscores the importance of robust QA tools in this domain as the market progresses through 2025 and beyond.

Dose calculation is another key application area, where AI-powered platforms are transforming the way radiation doses are computed and verified. Accurate dose calculation is essential for maximizing tumor control while minimizing damage to surrounding healthy tissues. Traditional dose calculation methods are often time-consuming and susceptible to human error, particularly in complex cases involving multiple treatment modalities. AI-enhanced QA tools automate the verification process, enabling real-time assessment of dose distributions and rapid identification of discrepancies. These capabilities not only improve the safety and efficacy of radiotherapy but also enhance workflow efficiency by reducing manual intervention and rework. The convergence of dose calculation AI with broader AI tele-oncology radiation dose scheduling platforms is opening new avenues for remote, coordinated cancer care delivery.

Image analysis is a rapidly growing application within the market, driven by the increasing use of advanced imaging modalities such as CT, MRI, and PET in radiotherapy planning. AI algorithms excel at processing and interpreting large volumes of imaging data, enabling the automated detection of anatomical structures, tumor boundaries, and potential artifacts. This not only streamlines the image segmentation process but also improves the consistency and reproducibility of radiotherapy plans. AI-powered image analysis tools can also assist in the identification of subtle changes in tumor morphology over time, supporting adaptive planning and personalized treatment strategies. As imaging technologies continue to evolve and multi-modal fusion becomes standard practice, the demand for sophisticated AI-driven image analysis solutions is expected to accelerate considerably through 2034.

Workflow automation is an emerging application area that addresses the need for greater efficiency and standardization in radiotherapy planning. AI-enhanced QA platforms can automate repetitive tasks, such as data entry, plan documentation, and report generation, freeing up valuable time for clinicians and medical physicists. By streamlining workflows and reducing administrative burden, these solutions enable healthcare providers to focus on delivering high-quality, patient-centered care. Workflow automation also facilitates the implementation of best practices and adherence to clinical guidelines, further enhancing the safety and effectiveness of radiotherapy treatments across institutions of varying size and complexity.

Other applications of AI-Enhanced Radiotherapy Planning QA solutions include adaptive planning, real-time treatment monitoring, and predictive analytics. These advanced use cases are gaining traction as healthcare providers seek to leverage AI technologies to deliver more personalized and responsive cancer care. The ability to continuously monitor and adjust treatment plans based on real-time patient data represents a significant leap forward in the field of radiation oncology. As the scope of applications continues to expand, the AI-Enhanced Radiotherapy Planning QA market is poised for sustained growth and innovation through the end of the forecast period in 2034.

End-User Analysis

The End-User segment of the AI-Enhanced Radiotherapy Planning QA market is comprised of hospitals, cancer treatment centers, research institutes, and others, each with unique requirements and adoption drivers. Hospitals represent the largest end-user group, accounting for a significant share of the market in 2025. The widespread adoption of radiotherapy as a primary cancer treatment modality, coupled with the increasing complexity of treatment planning, has prompted hospitals to invest in advanced QA solutions. AI-enhanced platforms enable hospitals to improve the accuracy and safety of radiotherapy treatments, reduce the risk of adverse events, and enhance patient outcomes. The ability to automate QA processes and integrate with existing electronic health record (EHR) systems is particularly appealing to hospital administrators seeking to optimize operational efficiency and regulatory compliance.

Cancer treatment centers are another major end-user group, with a strong focus on delivering cutting-edge, patient-centric care. These specialized facilities are often early adopters of advanced technologies, including AI-driven QA solutions, as they seek to differentiate themselves in a competitive market. Cancer treatment centers benefit from the ability to offer highly individualized radiotherapy plans, supported by robust QA processes that ensure optimal treatment efficacy and safety. The integration of AI-powered tools enables these centers to streamline workflows, reduce turnaround times, and enhance collaboration among multidisciplinary teams. As the demand for specialized cancer care continues to rise globally through 2034, cancer treatment centers are expected to remain a key growth driver for the AI-Enhanced Radiotherapy Planning QA market.

Research institutes play a critical role in advancing the state of the art in radiotherapy planning and quality assurance. These organizations are at the forefront of developing and validating new AI algorithms, conducting clinical trials, and generating evidence to support the adoption of AI-enhanced QA solutions in routine practice. Research institutes often collaborate with technology vendors, hospitals, and cancer centers to pilot innovative solutions and demonstrate their clinical utility. The growing emphasis on translational research and the need to bridge the gap between laboratory discoveries and clinical implementation are driving increased investment in AI-Enhanced Radiotherapy Planning QA tools within this segment as we move through 2025 and into the forecast period.

Other end-users, such as outpatient clinics, government healthcare agencies, and academic medical centers, are also contributing to market growth. These organizations are increasingly recognizing the value of AI-driven QA solutions in improving the quality and consistency of radiotherapy treatments. The adoption of cloud-based platforms and remote collaboration tools is enabling smaller facilities and resource-constrained settings to access advanced QA capabilities without the need for significant upfront investment. As awareness of the benefits of AI-enhanced radiotherapy planning continues to grow, we expect to see broader adoption across a diverse range of end-users through 2034.

In conclusion, the End-User segment is characterized by a diverse and dynamic landscape, with hospitals, cancer treatment centers, research institutes, and other organizations each playing a vital role in driving market growth. The unique needs and priorities of each end-user group are shaping the development and adoption of AI-Enhanced Radiotherapy Planning QA solutions, ensuring that the market remains responsive to evolving clinical, operational, and regulatory requirements.

Deployment Mode Analysis

The Deployment Mode segment of the AI-Enhanced Radiotherapy Planning QA market is bifurcated into on-premises and cloud-based solutions, each offering distinct advantages and challenges. On-premises deployment remains the preferred choice for many large hospitals and cancer treatment centers, particularly those with stringent data security and privacy requirements. These organizations often have the resources and infrastructure to support in-house deployment, enabling them to maintain full control over sensitive patient data and comply with regulatory mandates. On-premises solutions also offer greater customization and integration capabilities, allowing healthcare providers to tailor QA workflows to their specific needs. However, the high upfront costs and ongoing maintenance requirements associated with on-premises deployment can be a barrier for smaller facilities and resource-limited settings.

Cloud-based deployment is gaining significant traction in 2025, driven by the need for scalability, flexibility, and cost efficiency. Cloud-based AI-Enhanced Radiotherapy Planning QA solutions enable healthcare providers to access advanced QA capabilities without the need for significant capital investment in hardware and IT infrastructure. These platforms offer seamless updates, remote access, and enhanced collaboration among multidisciplinary teams, making them particularly attractive for organizations with distributed operations or limited technical resources. The ability to leverage cloud-based analytics and machine learning services also accelerates the development and deployment of new AI algorithms, ensuring that healthcare providers can stay at the forefront of innovation through the 2026-2034 forecast period.

The adoption of cloud-based deployment models is being facilitated by advances in data security, encryption, and compliance frameworks, which address concerns related to patient privacy and regulatory compliance. Leading vendors are investing heavily in robust cybersecurity measures and obtaining certifications such as HIPAA and GDPR compliance to reassure healthcare providers of the safety and integrity of cloud-based QA solutions. The growing acceptance of telemedicine and remote care models is also driving demand for cloud-based platforms that support real-time collaboration and plan validation across multiple locations.

Hybrid deployment models, which combine the strengths of on-premises and cloud-based solutions, are emerging as a popular choice for organizations seeking to balance security, scalability, and cost considerations. These models enable healthcare providers to retain sensitive data on-premises while leveraging the computational power and advanced analytics capabilities of the cloud for specific tasks. Hybrid deployment also facilitates seamless integration with existing systems and workflows, ensuring a smooth transition to AI-enhanced QA processes without disrupting established clinical routines.

In summary, the Deployment Mode segment is characterized by a dynamic and evolving landscape, with on-premises, cloud-based, and hybrid models each offering unique benefits and trade-offs. The choice of deployment mode is influenced by factors such as organizational size, technical capabilities, regulatory requirements, and budget constraints. As AI technologies continue to mature and healthcare providers seek to optimize radiotherapy planning and QA processes, the demand for flexible and scalable deployment options is expected to drive sustained growth in this segment through 2034.

Opportunities & Threats

The AI-Enhanced Radiotherapy Planning QA market presents a wealth of opportunities for innovation, growth, and improved patient outcomes. One of the most promising opportunities lies in the integration of AI-driven QA solutions with emerging technologies such as precision medicine, genomics, and real-time imaging. By leveraging comprehensive patient data and advanced analytics, healthcare providers can develop highly personalized radiotherapy plans that maximize treatment efficacy while minimizing side effects. The ability to continuously monitor and adjust treatment plans based on real-time feedback represents a paradigm shift in cancer care, enabling truly adaptive and responsive therapy. Furthermore, the growing adoption of cloud-based platforms and remote collaboration tools is democratizing access to advanced QA capabilities, enabling smaller facilities and resource-limited settings to benefit from the latest innovations in radiotherapy planning.

Another significant opportunity is the expansion of AI-Enhanced Radiotherapy Planning QA solutions into emerging markets, particularly in the Asia Pacific, Latin America, and Middle East and Africa regions. These regions are experiencing a rapid rise in cancer incidence, coupled with increasing investments in healthcare infrastructure and technology. By tailoring AI-driven QA solutions to the unique needs and constraints of these markets, vendors can unlock new growth avenues and contribute to the global fight against cancer. Additionally, partnerships between technology providers, research institutions, and healthcare organizations are fostering innovation and accelerating the development of next-generation QA tools. The ongoing evolution of regulatory frameworks and reimbursement models is also creating a more favorable environment for the adoption of AI-enhanced radiotherapy planning solutions through the mid-2030s.

Despite the numerous opportunities, the market faces several threats and restraints that could impede growth. One of the primary challenges is the high cost of implementing and maintaining AI-Enhanced Radiotherapy Planning QA solutions, particularly for smaller facilities and resource-constrained settings. The need for specialized hardware, ongoing software updates, and comprehensive training programs can be a significant financial burden. Additionally, concerns related to data security, patient privacy, and regulatory compliance continue to pose barriers to adoption, particularly in regions with stringent data protection laws. The complexity of integrating AI-driven QA tools with existing radiotherapy planning systems and workflows can also lead to operational challenges and resistance from clinicians and staff. Addressing these threats will require ongoing investment in education, support, and innovation to ensure that the benefits of AI-enhanced radiotherapy planning are accessible to all patients and providers worldwide.

Regional Outlook

The North American region currently leads the AI-Enhanced Radiotherapy Planning QA market, with a market size of approximately USD 201.4 million in 2025, representing around 40.5% of global revenue. This dominance is attributed to the region's advanced healthcare infrastructure, high adoption rate of novel technologies, and a robust ecosystem of leading technology vendors. The United States, in particular, is a hotbed for innovation in radiation oncology, supported by significant investments in research and development, favorable reimbursement policies, and a strong focus on patient safety and regulatory compliance. Canada is also witnessing steady growth, driven by government initiatives to modernize cancer care and expand access to advanced radiotherapy solutions. Over the forecast period, North America is expected to maintain its leadership position, with a projected CAGR of approximately 16.2% through 2034.

Get Free Sample Report

Europe follows closely, with a market size of around USD 129.3 million in 2025, accounting for approximately 26.0% of global revenue. The region's growth is fueled by increasing government support for cancer research, widespread adoption of AI technologies in healthcare, and a strong emphasis on quality assurance and patient safety. Countries such as Germany, the United Kingdom, France, and the Netherlands are at the forefront of implementing AI-driven QA solutions in radiotherapy planning, supported by collaborations between academic institutions, technology providers, and healthcare organizations. The European market is characterized by a high degree of regulatory oversight, which is driving demand for robust and compliant QA tools. As the region continues to invest in digital health and precision medicine, the adoption of AI-enhanced radiotherapy planning solutions is expected to accelerate through 2034.

The Asia Pacific region is poised for the highest growth rate, with a market size of approximately USD 106.9 million in 2025, representing 21.5% of global revenue, and a projected CAGR of approximately 22.3% through 2034. The rapid rise in cancer incidence, improving healthcare infrastructure, and increasing awareness of the benefits of AI-enhanced radiotherapy planning are key drivers of growth in this region. Countries such as China, India, Japan, and South Korea are making significant investments in cancer care, supported by government initiatives and public-private partnerships. The adoption of cloud-based and remote collaboration platforms is enabling healthcare providers in the region to overcome resource constraints and access advanced QA capabilities. Latin America and the Middle East and Africa, with market sizes of approximately USD 34.8 million and USD 24.9 million respectively in 2025, are also expected to witness steady growth as healthcare systems in these regions continue to evolve and adopt advanced cancer treatment modalities.

Competitor Outlook

The AI-Enhanced Radiotherapy Planning QA market in 2025 is characterized by a highly competitive and dynamic landscape, with a mix of established players, emerging startups, and research-driven organizations vying for market share. Leading vendors are investing heavily in research and development to enhance the capabilities of their AI-driven QA platforms, focusing on features such as adaptive planning, real-time analytics, and seamless integration with existing radiotherapy systems. The competitive landscape is further shaped by strategic partnerships, collaborations, and mergers and acquisitions, as companies seek to expand their product portfolios, enter new markets, and strengthen their technological capabilities. Intellectual property and proprietary algorithms are key differentiators in this market, with vendors striving to develop unique solutions that deliver superior accuracy, efficiency, and clinical utility.

Innovation is a key driver of competition in the market, with companies racing to develop next-generation QA tools that leverage the latest advances in AI, machine learning, and data analytics. The ability to offer integrated, end-to-end solutions that address the full spectrum of radiotherapy planning QA needs is becoming increasingly important, as healthcare providers seek to simplify procurement, deployment, and support. Customer support, training, and ongoing service are also critical differentiators, as healthcare organizations require expert guidance to ensure the successful adoption and utilization of AI-driven QA solutions. The market is witnessing a growing emphasis on user experience, interoperability, and customization, as vendors strive to meet the diverse needs of hospitals, cancer treatment centers, and research institutes. The evolution of adjacent fields such as AI-generated radiology report QA is also influencing competitive strategies, as vendors look to bundle complementary capabilities into unified oncology AI platforms.

The competitive landscape is also influenced by the emergence of new entrants and disruptive startups, which are bringing fresh perspectives and innovative solutions to the market. These companies are leveraging advances in cloud computing, big data analytics, and open-source frameworks to develop cost-effective and scalable QA tools. Collaborations with academic institutions and research organizations are enabling startups to validate their solutions in real-world clinical settings and generate evidence to support regulatory approval and market adoption. As the market continues to evolve through 2034, we expect to see increased competition and consolidation, as established players seek to acquire innovative startups and expand their technological capabilities.

Some of the major companies operating in the AI-Enhanced Radiotherapy Planning QA market include Varian Medical Systems (a Siemens Healthineers company), Elekta AB, RaySearch Laboratories, Mirada Medical, MIM Software, Sun Nuclear Corporation (a Mirion Technologies company), Brainlab AG, Vision RT, IBA Dosimetry, Radformation, Limbus AI, MVision AI, TheraPanacea, Accuray Incorporated, and Philips Healthcare. Varian Medical Systems is a global leader in radiation oncology, offering a comprehensive portfolio of AI-driven QA solutions widely adopted in hospitals and cancer treatment centers worldwide. Elekta AB is known for its innovative radiotherapy platforms and strong focus on AI integration, while RaySearch Laboratories specializes in advanced treatment planning and QA software. Mirada Medical and MIM Software are recognized for their cutting-edge image analysis and workflow automation tools, which are increasingly being integrated into radiotherapy planning workflows globally.

Sun Nuclear Corporation, now part of Mirion Technologies, is a key player in the QA segment, offering a range of hardware and software solutions for radiotherapy plan verification and validation. Brainlab AG and Vision RT are making significant contributions to the market with a focus on adaptive planning, image-guided radiotherapy, and real-time treatment monitoring. Radformation, Limbus AI, and MVision AI represent the new generation of AI-native vendors, developing specialized deep learning platforms for auto-segmentation, plan QA, and contouring. TheraPanacea brings AI-powered decision support specifically designed for radiation oncology departments in Europe and beyond. These companies are actively investing in research and development, strategic partnerships, and global expansion to strengthen their market positions and drive innovation in AI-enhanced radiotherapy planning QA through 2034 and beyond.

Key Players

• Varian Medical Systems (Siemens Healthineers)
• Elekta AB
• RaySearch Laboratories
• Mirada Medical
• MIM Software
• Sun Nuclear Corporation (Mirion Technologies)
• Brainlab AG
• Vision RT
• IBA Dosimetry
• Radformation
• Limbus AI
• MVision AI
• TheraPanacea
• Accuray Incorporated
• Philips Healthcare